Funding influences exposure and review of cancer research

Funding influences exposure and review of cancer research
Abstracts submitted to the American Society of Clinical Oncology annual meeting by researchers who have financial relationships with commercial interests are more prominently placed and more favorably scored by peers, according to research published online June 17 in the Journal of Clinical Oncology.

(HealthDay)—Abstracts submitted to the American Society of Clinical Oncology (ASCO) annual meeting by researchers who have financial relationships with commercial interests are more prominently placed and more favorably scored by peers, according to research published online June 17 in the Journal of Clinical Oncology.

Beverly Moy, M.D., M.P.H., of the Massachusetts General Hospital Cancer Center in Boston, and colleagues analyzed 20,718 abstracts presented at ASCO meetings in 2006 and 2008 to 2011. The association of financial conflicts of interest (FCOIs) with meeting placement and peer review score was examined. On a scale of 1 to 5, lower peer-reviewed scores indicated greater scientific merit.

The researchers found that 36 percent of the abstracts had at least one author who reported an FCOI. A significant increase in the proportion of abstracts with any FCOI was observed for 2011 (38 percent) compared with 2006 (33 percent). Compared with general posters, abstracts with FCOIs were significantly more likely to receive placement (in descending order of meeting prominence) in plenary session (odds ratio [OR], 7.3), clinical science symposium (OR, 2.2), oral presentation (OR, 1.9), and poster discussion (OR, 1.7). For all abstracts except publish-only, those with FCOIs had a significantly more favorable mean peer-reviewed score (2.62) compared with those without FCOIs (2.73).

"Real and perceived financial conflicts of interest and risks of bias in the conduct and reporting of research represent important issues that necessitate strategies to safeguard the public," writes the author of an accompanying editorial.

Several study authors and the editorial author disclosed to the biomedical and/or .

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

More cutting-edge cancer research supported by industry

date May 17, 2012

Nearly half of the research presented at ASCO's annual meeting last year came from researchers with ties to companies, and the amount appears to be increasing every year, according to new findings from Fox Chase Cancer Center. ...

ASCO: Cancer patients want to talk about costs with docs

date May 31, 2013

(HealthDay)—Although financial distress is common, even in insured patients, discussion of costs of cancer care with doctors rarely happens, according to research to be presented at the annual meeting of ...

Recommended for you

Spicy treatment the answer to aggressive cancer?

date Jul 03, 2015

It has been treasured by food lovers for thousands of years for its rich golden colour, peppery flavour and mustardy aroma…and now turmeric may also have a role in fighting cancer.

Cancer survivors who smoke perceive less risk from tobacco

date Jul 02, 2015

Cancer survivors who smoke report fewer negative opinions about smoking, have more barriers to quitting, and are around other smokers more often than survivors who had quit before or after their diagnosis, according to a ...

Melanoma mutation rewires cell metabolism

date Jul 02, 2015

A mutation found in most melanomas rewires cancer cells' metabolism, making them dependent on a ketogenesis enzyme, researchers at Winship Cancer Institute of Emory University have discovered.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.